-
公开(公告)号：US5854403A
公开(公告)日：1998-12-29
申请号：US653298
申请日：1996-05-24
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00 , C07K1/14
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt. The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant rvWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active. Further, the invention relates to a pharmaceutical preparation that contains rvWF, which comprises mulitimers with a high structural integrity.
摘要翻译： 本发明涉及一种用于分离高纯度血管性血友病因子的方法，其中重组血管性血友病因子（rvWF）通过阴离子交换色谱在季氨基型阴离子交换剂上在包含缓冲物质和任选盐的缓冲溶液中进行色谱纯化。 缓冲溶液优选不含稳定剂，氨基酸和其它添加剂。 根据该方法，可以获得高纯度的重组rvWF，其不含血浆蛋白质，特别是不含因子VIII，且具有生理活性。 此外，本发明涉及含有rvWF的药物制剂，其包含具有高结构完整性的多组分。
-
12.发明授权公开(公告)号：US06352856B1
公开(公告)日：2002-03-05
申请号：US09228625
申请日：1999-01-12
IPC分类号： C12N1500
CPC分类号： C12N15/86 , C12N2710/24143 , C12N2740/13044
摘要： A chimeric poxvirus is disclosed, which comprises the sequences of the vector component of a retroviral vector particle and optionally the packaging component of a defective retroviral particle. The chimeric poxvirus according to the invention particularly can be used for applications in gene therapy or tumor therapy.
摘要翻译： 公开了一种嵌合痘病毒，其包含逆转录病毒载体颗粒的载体组分和任选的缺陷型逆转录病毒颗粒的包装组分的序列。 根据本发明的嵌合痘病毒特别可用于基因治疗或肿瘤治疗中的应用。
-
公开(公告)号：US5880265A
公开(公告)日：1999-03-09
申请号：US898129
申请日：1997-07-22
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.
-
14.发明授权Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods 有权改良痘病毒，包括基于重组药物敏感性痘苗病毒的改良天花病毒疫苗，以及新的选择方法公开(公告)号：US08753648B2
公开(公告)日：2014-06-17
申请号：US11304578
申请日：2005-12-16
IPC分类号： A61K48/00 , A61K39/42 , A61K39/12 , A61K39/275 , C12N7/00
CPC分类号： C12N15/86 , A61K39/00 , A61K39/12 , A61K39/275 , A61K2039/525 , A61K2039/5256 , C07K2319/00 , C12N9/1211 , C12N2710/24143 , C12N2770/24143
摘要： The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.
摘要翻译： 本发明提供了重组痘病毒，例如痘苗病毒，其含有整合的外源序列，例如外源基因，其编码可以将前药转化成药物的前体药物转化多肽，所述药物可以防止病毒复制或对病毒有毒性。 重组痘病毒可适用于疫苗。 本发明还提供了抑制病毒复制的方法，接种方法和治疗接种疫苗的受试者的方法，这些受试者显示出接种疫苗引起的疾病的风险。
-
公开(公告)号：US07998488B2
公开(公告)日：2011-08-16
申请号：US12271522
申请日：2008-11-14
IPC分类号： A61K39/285 , C12N7/00 , C12N7/01
CPC分类号： A61K9/1694 , A61K9/1623 , A61K9/1688 , A61K39/12 , A61K39/285 , Y02A50/388 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/466 , Y02A50/478 , Y02A50/484
摘要： A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between −10° C. and −30° C. or between −20° C. and −23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.
摘要翻译： 一种液体或液体冷冻组合物，其包含：修饰的痘苗安卡拉（MVA）病毒或其变体或衍生物和甘露糖醇，其中甘露糖醇是组合物的唯一稳定剂。 甘露醇可以在0至+ 10℃或液体冷冻组合物中提供稳定作用，例如在-10℃至-30℃之间或-20℃至-2.3.5℃之间。 MVA可以用作哺乳动物，优选人类的疫苗或用于基因治疗，病毒治疗，免疫治疗或癌症治疗。
-
公开(公告)号：US20100189745A1
公开(公告)日：2010-07-29
申请号：US12639917
申请日：2009-12-16
IPC分类号： A61K39/145 , C12N7/00
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5258 , C12N7/00 , C12N2760/16134 , C12N2760/16161
摘要： The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A.
摘要翻译： 本发明一般涉及用于生产针对流感病毒的改进疫苗的材料和方法，其中所述疫苗包含具有血凝素基因的重配病毒和来自相同甲型流感病毒亚型或乙型流感病毒的病毒的神经氨酸酶基因 和来自不同甲型流感病毒亚型或乙型流感病毒的内部基因。 一方面，HA和NA基因和内部基因来自流感A的高致病性H5N1毒株。
-
公开(公告)号：US09884105B2
公开(公告)日：2018-02-06
申请号：US12639917
申请日：2009-12-16
IPC分类号： A61K39/145 , C12N7/00 , A61K39/12 , A61K39/00
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5258 , C12N7/00 , C12N2760/16134 , C12N2760/16161
摘要： The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A.
-
公开(公告)号：US20120201847A1
公开(公告)日：2012-08-09
申请号：US13178198
申请日：2011-07-07
IPC分类号： A61K39/285 , A61P37/04 , A61K39/235 , A61K39/245 , A61K39/25 , A61K39/29 , A61K39/155 , A61K39/04 , A61K39/095 , A61K39/10 , A61K39/112 , A61K39/118 , A61K39/015 , A61K39/008 , A61K39/005 , A61K39/13 , A61K39/145 , A61K39/21 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/22 , A61P31/04 , A61P33/02 , A61K39/002 , A61P31/20
CPC分类号： A61K9/1694 , A61K9/1623 , A61K9/1688 , A61K39/12 , A61K39/285 , Y02A50/388 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/466 , Y02A50/478 , Y02A50/484
摘要： A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between −10° C. and −30° C. or between −20° C. and −23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.
摘要翻译： 一种液体或液体冷冻组合物，其包含：修饰的痘苗安卡拉（MVA）病毒或其变体或衍生物和甘露糖醇，其中甘露糖醇是组合物的唯一稳定剂。 甘露醇可以在0至+ 10℃或液体冷冻组合物中提供稳定作用，例如在-10℃至-30℃之间或-20℃至-2.3.5℃之间。 MVA可以用作哺乳动物，优选人类的疫苗或用于基因治疗，病毒治疗，免疫治疗或癌症治疗。
-
19.发明申请公开(公告)号：US20050196397A1
公开(公告)日：2005-09-08
申请号：US11093103
申请日：2005-03-28
申请人： Friedrich Scheiflinger , Randolf Kerschbaumer , Falko-Guenter Falkner , Friedrich Domer , Hans-Peter Schwarz
发明人： Friedrich Scheiflinger , Randolf Kerschbaumer , Falko-Guenter Falkner , Friedrich Domer , Hans-Peter Schwarz
IPC分类号： C12N15/09 , A61K39/395 , A61P7/04 , C07K16/18 , C07K16/36 , C07K16/40 , C12N5/10 , C12N5/12 , C12N5/20 , C12N15/02 , C12N15/13 , C12P21/02 , C12P21/08
CPC分类号： C07K16/40 , A61K2039/505
摘要： An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
摘要翻译： 针对因子IX /活化因子IX（FIXa）的抗体或抗体衍生物，其增加FIXa的促凝血活性。
-
公开(公告)号：US20100124557A1
公开(公告)日：2010-05-20
申请号：US12271522
申请日：2008-11-14
IPC分类号： A61K39/12
CPC分类号： A61K9/1694 , A61K9/1623 , A61K9/1688 , A61K39/12 , A61K39/285 , Y02A50/388 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/466 , Y02A50/478 , Y02A50/484
摘要： A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between −10° C. and −30° C. or between −20° C. and −23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.
摘要翻译： 一种液体或液体冷冻组合物，其包含：修饰的痘苗安卡拉（MVA）病毒或其变体或衍生物和甘露糖醇，其中甘露糖醇是组合物的唯一稳定剂。 甘露醇可以在0至+ 10℃或液体冷冻组合物中提供稳定作用，例如在-10℃至-30℃之间或-20℃至-2.3.5℃之间。 MVA可以用作哺乳动物，优选人类的疫苗或用于基因治疗，病毒治疗，免疫治疗或癌症治疗。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.028 秒)
